Product Code: VMR11219396
Value Market Research deeply researched the Global Opioids Use Disorder Market to foresee a significant growth in the industry over the upcoming years. The global opioids use disorder market report provides a complete industry analysis, market size, market share, growth trends, and forecasts for 2023 to 2028. The report starts with a detailed market introduction and an executive summary that highlights the report's key growth numbers. The subsequent chapters discuss the value chain of the market, Porter's Five Forces Model, and market attractiveness analysis. An exclusive chapter on COVID-19 impact analysis has been added to understand how the market has responded to the pandemic.
The market dynamics section of the report elaborates the current market drivers, restraints along with the challenges/risks and upcoming opportunities. This section can be of high interest for any company's strategists and new product development department. The global opioids use disorder market study segments the market and provides the market size in terms of revenue and/ or sales. This data is bifurcated by region and later by countries. The data is collected through detailed primary interviews and industry experts across the world. The detailed methodology can be seen in our sample reports. These market estimates are also influenced by the latest social, political and economic changes along with the current market dynamics that are affecting this opioids use disorder market.
The next sections of the opioids use disorder market report studies the market competitiveness and profiles some key market players/manufacturers. These sections are knowledgeable for understanding the competitor's product-line, their financials, recent developments and the top market share owners in the industry.
Countries Covered in the report are as below:
North America: United States, Canada, and Mexico
Europe: United Kingdom, Germany, France, Italy, Russia, Spain & Rest of Europe
Asia-Pacific: China, India, Japan, South Korea, Australia & Rest of APAC
Latin America: Brazil, Argentina, Peru, Chile & Rest of Latin America
Middle East and Africa: Saudi Arabia, UAE, Israel, South Africa
Market Segmentation in the report is as below:
By Drug Type
Agonist (Type[Methadone, Buprenorphine])
Antagonist
By Age group
19 to 39
40 to 59
Age 60 and over
By Route of Administration
Oral
Intravenous
Sublingual
By Distribution channal
Hospital Pharmacy
Retail Pharmacy
TABLE OF CONTENTS
1 . PREFACE
- 1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3 . OPIOIDS USE DISORDER - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Age group
- 3.7.3 Market Attractiveness Analysis By Route Of Administration
- 3.7.4 Market Attractiveness Analysis By Distribution channal
- 3.7.5 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
- 5.1. Impact Analysis of Covid-19 Outbreak
- 5.1.1. Direct Impact on Production
- 5.1.2. Supply Chain and Market Disruption
- 5.1.3. Financial Impact on Firms and Financial Markets
- 5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
- 5.3. Market: Pre V/S Post COVID-19
- 5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
- 5.5. COVID-19: Micro and Macro Factor Analysis
6 . GLOBAL OPIOIDS USE DISORDER MARKET ANALYSIS BY DRUG TYPE
- 6.1 Overview by Drug Type
- 6.2 Historical and Forecast Data
- 6.3 Analysis by Drug Type
- 6.4 Agonist (Type (Methadone, Buprenorphine)) Historic and Forecast Sales by Regions
- 6.5 Antagonist Historic and Forecast Sales by Regions
7 . GLOBAL OPIOIDS USE DISORDER MARKET ANALYSIS BY AGE GROUP
- 7.1 Overview by Age group
- 7.2 Historical and Forecast Data
- 7.3 Analysis by Age group
- 7.4 19 To 39 Historic and Forecast Sales by Regions
- 7.5 40 To 59 Historic and Forecast Sales by Regions
- 7.6 Age 60 And Over Historic and Forecast Sales by Regions
8 . GLOBAL OPIOIDS USE DISORDER MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
- 8.1 Overview by Route Of Administration
- 8.2 Historical and Forecast Data
- 8.3 Analysis by Route Of Administration
- 8.4 Oral Historic and Forecast Sales by Regions
- 8.5 Intravenous Historic and Forecast Sales by Regions
- 8.6 Sublingual Historic and Forecast Sales by Regions
9 . GLOBAL OPIOIDS USE DISORDER MARKET ANALYSIS BY DISTRIBUTION CHANNAL
- 9.1 Overview by Distribution channal
- 9.2 Historical and Forecast Data
- 9.3 Analysis by Distribution channal
- 9.4 Hospital Pharmacy Historic and Forecast Sales by Regions
- 9.5 Retail Pharmacy Historic and Forecast Sales by Regions
10 . GLOBAL OPIOIDS USE DISORDER MARKET ANALYSIS BY GEOGRAPHY
- 10.1. Regional Outlook
- 10.2. Introduction
- 10.3. North America Sales Analysis
- 10.3.1. Overview, Historic and Forecast Sales Analysis
- 10.3.2. North America By Segment Sales Analysis
- 10.3.3. North America By Country Sales Analysis
- 10.3.4. United State Sales Analysis
- 10.3.5. Canada Sales Analysis
- 10.3.6. Mexico Sales Analysis
- 10.4. Europe Sales Analysis
- 10.4.1. Overview, Historic and Forecast Sales Analysis
- 10.4.2. Europe by Segment Sales Analysis
- 10.4.3. Europe by Country Sales Analysis
- 10.4.4. United Kingdom Sales Analysis
- 10.4.5. France Sales Analysis
- 10.4.6. Germany Sales Analysis
- 10.4.7. Italy Sales Analysis
- 10.4.8. Russia Sales Analysis
- 10.4.9. Rest Of Europe Sales Analysis
- 10.5. Asia Pacific Sales Analysis
- 10.5.1. Overview, Historic and Forecast Sales Analysis
- 10.5.2. Asia Pacific by Segment Sales Analysis
- 10.5.3. Asia Pacific by Country Sales Analysis
- 10.5.4. China Sales Analysis
- 10.5.5. India Sales Analysis
- 10.5.6. Japan Sales Analysis
- 10.5.7. South Korea Sales Analysis
- 10.5.8. Australia Sales Analysis
- 10.5.9. Rest Of Asia Pacific Sales Analysis
- 10.6. Latin America Sales Analysis
- 10.6.1. Overview, Historic and Forecast Sales Analysis
- 10.6.2. Latin America by Segment Sales Analysis
- 10.6.3. Latin America by Country Sales Analysis
- 10.6.4. Brazil Sales Analysis
- 10.6.5. Argentina Sales Analysis
- 10.6.6. Peru Sales Analysis
- 10.6.7. Chile Sales Analysis
- 10.6.8. Rest of Latin America Sales Analysis
- 10.7. Middle East & Africa Sales Analysis
- 10.7.1. Overview, Historic and Forecast Sales Analysis
- 10.7.2. Middle East & Africa by Segment Sales Analysis
- 10.7.3. Middle East & Africa by Country Sales Analysis
- 10.7.4. Saudi Arabia Sales Analysis
- 10.7.5. UAE Sales Analysis
- 10.7.6. Israel Sales Analysis
- 10.7.7. South Africa Sales Analysis
- 10.7.8. Rest Of Middle East And Africa Sales Analysis
11 . COMPETITIVE LANDSCAPE OF THE OPIOIDS USE DISORDER COMPANIES
- 11.1. Opioids Use Disorder Market Competition
- 11.2. Partnership/Collaboration/Agreement
- 11.3. Merger And Acquisitions
- 11.4. New Product Launch
- 11.5. Other Developments
12 . COMPANY PROFILES OF OPIOIDS USE DISORDER INDUSTRY
- 12.1. Top Company Share Analysis
- 12.2. Market Concentration Rate
- 12.3. Alkermes Inc.
- 12.3.1. Company Overview
- 12.3.2. Company Revenue
- 12.3.3. Products
- 12.3.4. Recent Developments
- 12.4. AstraZeneca plc
- 12.4.1. Company Overview
- 12.4.2. Company Revenue
- 12.4.3. Products
- 12.4.4. Recent Developments
- 12.5. BioDelivery Sciences International Inc.
- 12.5.1. Company Overview
- 12.5.2. Company Revenue
- 12.5.3. Products
- 12.5.4. Recent Developments
- 12.6. Braeburn Pharmaceuticals
- 12.6.1. Company Overview
- 12.6.2. Company Revenue
- 12.6.3. Products
- 12.6.4. Recent Developments
- 12.7. Camurus
- 12.7.1. Company Overview
- 12.7.2. Company Revenue
- 12.7.3. Products
- 12.7.4. Recent Developments
- 12.8. Dr Reddy Laboratories Ltd
- 12.8.1. Company Overview
- 12.8.2. Company Revenue
- 12.8.3. Products
- 12.8.4. Recent Developments
- 12.9. Pear Therapeutics
- 12.9.1. Company Overview
- 12.9.2. Company Revenue
- 12.9.3. Products
- 12.9.4. Recent Developments
- 12.10. Hikma Pharmaceuticals PLC
- 12.10.1. Company Overview
- 12.10.2. Company Revenue
- 12.10.3. Products
- 12.10.4. Recent Developments
- 12.11. Mallinckrodt Pharmaceuticals
- 12.11.1. Company Overview
- 12.11.2. Company Revenue
- 12.11.3. Products
- 12.11.4. Recent Developments
- 12.12. NYC Health Hospitals
- 12.12.1. Company Overview
- 12.12.2. Company Revenue
- 12.12.3. Products
- 12.12.4. Recent Developments
- 12.13. Orexo AB
- 12.13.1. Company Overview
- 12.13.2. Company Revenue
- 12.13.3. Products
- 12.13.4. Recent Developments
- 12.14. OREXO AB
- 12.14.1. Company Overview
- 12.14.2. Company Revenue
- 12.14.3. Products
- 12.14.4. Recent Developments
- 12.15. Indivior PLC
- 12.15.1. Company Overview
- 12.15.2. Company Revenue
- 12.15.3. Products
- 12.15.4. Recent Developments
- 12.16. Reckitt Benckiser Pharmaceuticals Inc
- 12.16.1. Company Overview
- 12.16.2. Company Revenue
- 12.16.3. Products
- 12.16.4. Recent Developments
- 12.17. Sandoz
- 12.17.1. Company Overview
- 12.17.2. Company Revenue
- 12.17.3. Products
- 12.17.4. Recent Developments
- 12.18. Titan Pharmaceuticals Inc.
- 12.18.1. Company Overview
- 12.18.2. Company Revenue
- 12.18.3. Products
- 12.18.4. Recent Developments
- 12.19. Viatris Inc
- 12.19.1. Company Overview
- 12.19.2. Company Revenue
- 12.19.3. Products
- 12.19.4. Recent Developments
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies